my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
21-02-2005: Biotest AG and Lonza have concluded a manufacturing agreement in January 2005 for further production of GMP grade consistency batches of Biotest´s monoclonal antibody BT-061. The production, which has already commenced this week supplies Biotest with material for further clinical studies. In addition, this agreement opens up the option on future large scale production with the technological leader Lonza.
BT-061 is directed against a novel target on T-cells mediating a unique, immunoregulatory mechanism of action. The candidate is Biotest´s most advanced monoclonal antibody and has shown tolerability and efficacy in early clinical trials in patients with rheumatoid arthritis. With the clinical material produced by Lonza Biologics, Slough, UK, development will continue in rheumatoid arthritis and psoriasis.
Watchlist
This is where you can add this news to your personal favourites
Biotest AG: First time Revenue and EBIT contribution by Biotherapeutics Segment
The Biotest Group has increased sales in the first half of 2011 in it's continuing operations (Plasma Proteins and Biotherapeutics) by 4,9 % to EUR 212,9 million compared to EUR 202.9 million in the previous year period. The increase was largely attributable to an upfront payment under a de ... more
Merck Millipore Completed Acquisition of Microbiology Business of Biotest AG
Merck Millipore announced that it has completed the acquisition of the microbiology business of Biotest AG, Dreieich, Germany. All relevant authorities approved the sale of Biotest´s woldwide Microbiological Monitoring business activities, which consist of the product portfolio of Hycon (hy ... more
Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway to study it ... more
Biotest is a company specialising in innovative haematology and immunology products with the holistic approach of a global pharmaceutical, diagnostics and biotherapeutics group. Its approximately 2,000 employees develop, manufacture and sell medicinal products for the treatment of blood and ... more
Lonza and Hyglos reach agreement for endotoxin detection patents
Lonza Walkersville, Inc. and Hyglos GmbH announced that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection. Specifically, the agreement allows Hyglos to use recombinant factor ... more
The National Institutes of Health Center for Regenerative Medicine (NIH) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) for research purposes. By definition, iPSCs have the ability to indefinitely self-renew and become any cell type in the ... more
Avalanche Biotechnologies, Inc. and Lonza announced a manufacturing collaboration focused on process development and scale-up efforts for the manufacturing of adeno-associated viral (AAV) vectors for gene therapy. AAV vectors are rapidly becoming one of the most promising gene delivery vehi ... more
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
